# Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)

> **NCT05013112** · NA · COMPLETED · sponsor: **West China Hospital** · enrollment: 105 (actual)

## Conditions studied

- Kidney Transplantation
- Metabolic Disorder
- Metformin
- Empagliflozin

## Interventions

- **DRUG:** SGLT2 inhibitor
- **DRUG:** Metformin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05013112
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05013112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05013112, "Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05013112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*